01Madrigal Pharmaceuticals reported Q3 2026 EPS of $1.83, beating estimates by $2.92 and swinging to profitability from expected losses.
02Revenue reached $431.3M, exceeding the $404.1M estimate by approximately $27.2M in the third quarter.
03The company's stock trades at $472.51 with a $12.7B market capitalization following the earnings release.
04This quarter marks a significant turnaround after three consecutive quarters of losses in Q4 2025 through Q1 2026.
05Earnings surprises of this magnitude historically trigger analyst estimate revisions and can influence institutional investor positioning.
Earnings Results
Madrigal Pharmaceuticals (NASDAQ:MDGL) reported quarterly earnings results on November 03, 2026 that exceeded analyst expectations.
The Healthcare company reported earnings per share of $1.83, beating the consensus estimate of $-1.09 by $2.92 per share. Revenue came in at $431.3M, beating the estimate of $404.1M.
Company Overview
Madrigal Pharmaceuticals's stock moved following the earnings release. The stock currently trades at $472.51 with a market capitalization of $12.7B.
Madrigal Pharmaceuticals's earnings outperformance reflects execution that exceeded Wall Street's expectations. Earnings beats can lead to upward estimate revisions from analysts, which often correlate with sustained stock price appreciation over the following weeks as models are updated.
The 268% beat relative to consensus estimates is a notable deviation. Earnings surprises of this magnitude often trigger analyst revisions and can influence institutional positioning in the weeks following the report.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Madrigal Pharmaceuticals should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.